Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy

C Y Cheah¹,², M S Hofman²,³, M Dickinson¹,², A Wirth²,⁴, D Westerman¹, S J Harrison¹,², K Burbury¹, M Wolf¹,², H Januszewicz¹, K Herbert¹,², H M Prince¹,²,⁵, D A Carney¹,², D S Ritchie¹,², R J Hicks²,³ and J F Seymour*,¹,²

¹Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; ²University of Melbourne, Melbourne, VIC, Australia; ³Centre for Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; ⁴Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia and ⁵Monash University, Melbourne, VIC, Australia

Background: The usefulness of positron emission tomography with computed tomography (PET–CT) in the surveillance of patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission after primary therapy is not well studied.

Methods: We performed a retrospective review of our database between 2002 and 2009 for patients with de novo DLBCL who underwent surveillance PET–CT after achieving complete metabolic response (CMR) following primary therapy.

Results: Four-hundred and fifty scans were performed in 116 patients, with a median follow-up of 53 (range 8–133) months from completion of therapy. Thirteen patients (11%) relapsed: seven were suspected clinically and six were subclinical (all within first 18 months). The positive predictive value in patients with international prognostic index (IPI) ≥3 was 56% compared with 80% in patients with IPI <3. Including indeterminate scans, PET–CT retained high sensitivity 95% and specificity 97% for relapse.

Conclusion: Positron emission tomography with computed tomography is not useful in patients for the majority of patients with diffuse large B-cell lymphoma in CMR after primary therapy, with the possible exception of patients with baseline IPI ≥3 in the 18 months following completion of primary therapy. This issue could be addressed by a prospective clinical trial.

Despite improvements in cure rates for patients with diffuse large B-cell lymphoma (DLBCL), up to 40% relapse, mostly within 18 months from treatment (Armitage, 2007). There is no consensus as to the most appropriate form of post-remission surveillance. Salvage chemotherapy and subsequent high-dose therapy with autologous transplantation is potentially applicable for selected patients up to age 75 and can cure up to 40% of patients who relapse (Kewalramani et al, 2004; Jantunen et al, 2008). However, this approach is less likely to be successful in those in whom relapse occurs early after primary therapy (Gisselbrecht et al, 2010). The established prognostic factors for response to salvage including relapse stage, elevated serum lactate dehydrogenase (LDH) and bulk reflect tumour burden, suggesting early detection may increase the likelihood of cure (Hamlin et al, 2003).

Current guidelines recommend clinical review every 3–6 months after completion of therapy for 5 years and annually thereafter with computed tomography (CT) scans at 6 month intervals up to 2 years (National Comprehensive Cancer Network, 2012; Tilly et al, 2010). Despite this, there is little evidence to support the use of CT with 83–89% of relapses being detected by
symptoms despite surveillance scans (Weeks et al, 1991; Elis et al, 2002; Guppy et al, 2003). Positron emission tomography combined with computer tomography (PET–CT) has become the modality of choice for initial staging and end of treatment assessment in DLBCL (Hicks et al, 2005; Cheson, 2011). The improved sensitivity of PET–CT suggests advantages over CT in the detection of subclinical relapse. Few studies have examined the role of PET–CT surveillance in patients with DLBCL achieving remission after primary therapy (Zinzani et al, 2009; Petrasch et al, 2010; El-Galaly et al, 2011; Goldschmidt et al, 2011; Abel et al, 2012). Liedtke et al (2006) found patients with subclinical relapse were more likely to have lower second-line IPI (RR 4, 95% CI 0.58–27.6) with a non-significant trend towards survival benefit (actuarial 5 year survival of 54% vs 43%; P = 0.13). The aim of our study was to evaluate the role of 18F-fluorodeoxyglucose (FDG) PET–CT scans in the surveillance of patients achieving complete metabolic response (CMR) after primary therapy for DLBCL, and define a risk-adapted strategy for surveillance imaging.

MATERIALS AND METHODS

We conducted a retrospective review of patients with DLBCL who underwent PET–CT scanning at the Peter MacCallum Cancer Centre. Data collection was compliant with the institutional ethics requirements. In the period analysed, departmental protocol recommended 6-monthly PET–CT scans for patients in CMR, for the first 2 years, and then annually until 5 years after completion of therapy for patients in whom there existed intention to intervene if subclinical relapse was identified. In most cases, this intervention consisted of intensive salvage chemotherapy following by autologous stem cell transplantation. Implementation was at the discretion of the treating physician. We included patients who had a confirmed diagnosis of de novo DLBCL treated at our centre between 1st January 2002 and 31st December 2009 who had achieved CMR at the completion of primary therapy and underwent at least one surveillance PET–CT scan.

We identified 200 patients with DLBCL within the specified time period. Eighty-four were ineligible for the following reasons: histological transformation from a variety of indolent lymphoma subtypes (n = 29), no surveillance PET–CT scans performed (presumed non-adherent patients aged over 70 or otherwise unfit for intensification, n = 26), did not achieve CMR (n = 14), end of treatment PET positive for another reason for example, sarcoidosis or infection (n = 7), palliative management only (n = 5), had prior chemotherapy at another institution (n = 3). Only two patients without surveillance PET scans relapsed within 6 months of completing therapy (3.2 and 5.4 months) only one of whom was a suitable candidate for autologous stem cell transplant.

Of the cohort (n = 116) analysed, the median was age 59 years (range 16–85), 54% were male and 51% had an elevated serum LDH. Eastern Cooperative Oncology Group performance status was ≤1 in 96% of patients, with <2 sites of extranodal involvement in 75% and baseline international prognostic index (IPI; 1993)—determined using PET–CT and bone marrow biopsy was <3 in 77 (66%) and ≥3 in 37 (32%) of patients. In two patients, baseline IPI could not be calculated due to missing data. Initial immunochemotherapy was R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) in 110 (95%), while six (5%) received R-Hyper-CVAD (rituximab, hyper-fractonated cyclophosphamide, vincristine, doxorubicin and dexamethasone) alternating with high-dose methotrexate and cytarabine at the discretion of the treating clinician due to the presence of high-risk features. Sixty-six patients (57%) received radiotherapy as consolidation for bulky or localised disease.

Data collection. For each patient, we collected baseline characteristics including sex, performance status, age, serum LDH, number of extranodal sites, IPI (A predictive model for aggressive non-Hodgkin’s lymphoma, 1993), primary therapy date and details of follow-up PET–CT scans, and follow-up data including the date and site of relapse, type (subclinical or suspected), relapse IPI, biopsy results, second malignancies, cause and date of death.

The primary end point was determination of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of PET–CT for the detection of relapse. 18F-FDG PET–CTs were obtained on a dedicated PET/CT scanner (Discovery LS, GE Medical Systems, Milwaukee, USA; Discovery STE, GE Medical Systems, Milwaukee, USA or Biograph 64, Siemens Medical Solutions, Knoxville, USA) from the skull-base to upper-thigh level, unless there was suspicion or known disease outside this field-of-view. Patients were fasted for 6 h before administration of 5 MBq kg⁻¹ 18F-FDG, to a maximum of 400 MBq adapted for weight and imaged after a ≥60-min uptake phase.

Definitions. PET reports were reviewed and classified as positive, negative or indeterminate for relapsed lymphoma by one (clinician) investigator blinded to patient outcome. In generating the original PET report, the imaging specialist had access to prior investigation results, including the baseline and post treatment FDG PET–CT studies. It should be noted that the time period covered by the study was mostly before the publication of both the International Harmonisation Project (Juweid et al, 2007) and the Deauville criteria (Meignan et al, 2009). A positive scan suggested relapsed lymphoma, with true-positive results requiring either biopsy confirmation or unequivocal scan progression. A false-positive scan was refuted by biopsy and/or follow-up showing resolution of areas of increased FDG uptake. A negative scan was interpreted as negative for relapsed lymphoma: true negatives had no clinical relapse and false negatives manifest relapse within 3 months from the date of the scan. Cases in which uncertainty in the interpretation of the scan existed (n = 26) were referred to a three member review panel (which included one imaging specialist) and re-scored with majority opinion accepted. For seven scans, no determination could be made and they were recorded as ‘indeterminate’. A ‘suspected relapse’ was defined as relapse preceded by signs, symptoms or other clinical features (such as rising serum LDH). A ‘subclinical relapse’ was defined as relapse detected without the above features, on the basis of imaging findings.

Statistical analysis. Continuous variables are expressed as median and range and compared using the unpaired t-test. Non-normally distributed variables are expressed as median and range, and compared using Mann–Whitney U-test. Categorical variables are reported as percentages, and compared using Fisher’s exact test. Event-free survival, overall survival (OS) and time to relapse were determined using the method of Kaplan and Meier, with curve comparisons using log-rank analysis. A P-value <0.05 was considered significant.

Results. In 116 patients, 450 surveillance PET–CT scans were performed with a median of four scans per patient (range 1–10). At 1st January 2012, with a median of 53 (range 8–133) months follow-up from completion of therapy, 13 patients (11%) had relapsed and 97 (84%) remain relapse-free in ongoing complete remission. Features associated with relapse in these patients are displayed in Table 1. Of those who relapsed, eight died from progressive disease and five are in remission after salvage therapy. Six patients died from other causes: gastric cancer (n = 2), pneumonia complicating oesophageal cancer (n = 1), ruptured abdominal aortic aneurysm (n = 1), metastatic squamous cell carcinoma (n = 1) and cause unknown, while in clinical remission (n = 1).
Test performance of PET–CT surveillance scanning. There were 13 true-positive scans, six false positives, no false negatives and 424 true negatives. The PPV was 68% and the NPV 100%. Of the seven indeterminate scans, six were shown by follow-up to be negative for lymphoma and one was biopsy confirmed to be positive. If we include indeterminate scans by scoring the former as false positives and the latter as false negatives, respectively, test performance remained robust with revised sensitivity 95%, specificity 97%, PPV 60% and NPV 99%. However, when considering patients with baseline IPI \( \geq 3 \) \( (n = 37) \) there were eight true positives, two false positives, no false negatives, 112 true negatives and two indeterminate scans. While sensitivity, specificity and NPV (100%) were essentially unchanged, the PPV increased to 80%. In patients with baseline IPI \( < 3 \) \( (n = 77) \), there were five true positives, four false positives, no false negatives, 312 true negatives and five indeterminate scans. This resulted in a lower PPV (56%). Most relapses (and therefore true-positive scans) occurred within the first 18 months. The number of scans needed to detect one subclinical relapse was analysed as a function of both baseline IPI \( \geq 3 \) vs \( < 3 \)}, as well as time following completion of primary therapy. Averaged over the first 18 months following completion of therapy, 92 scans were performed to detect one subclinical relapse in patients with baseline IPI \( < 3 \), but only 22 scans in patients with baseline IPI \( \geq 3 \) (86 scans to detect four subclinical relapses). Surveillance PET–CT had low yield after 18 months regardless of baseline IPI, with only one (clinically suspected) true-positive result in a patient (baseline IPI 3) from a total of 170 scans (Table 2).

Patterns of relapse. Two-thirds of relapses occurred within 18 months of completing chemotherapy and 85% within 2 years, with a median time to relapse of 12.8 months. The time distribution of suspected relapses occurred at sites, which were previously uninvolved by DLBCL. PET–CT was concordant in all seven cases, demonstrating CMR. A closed circle represents a ‘true positive’ that is, scan later proven to represent relapsed lymphoma.

Management of relapse. The median age of the 13 patients who relapsed (at the time of relapse) was 64 (range 21 to 82) years. All patients received salvage therapy, 11 with R-ICE (rituximab, ifosfamide, carboplatin and etoposide), one (who was 82) with R-CVP and one (who relapsed with follicular histology) with 131I-rituxmab (Leahy et al, 2006). Of the 11 patients receiving R-ICE, seven proceeded to cyclophosphamide, carmustine, etoposide conditioned autologous stem cell transplant. The remaining four patients did not proceed to transplant because their disease was refractory \( (n = 2) \) or they did not tolerate \( (n = 2) \) salvage chemotherapy. Six false-positive scans for recurrent lymphoma occurred at a median of 9.0 (range 3.9–25.1) months following completion of seven suspected relapses, four had second-line IPI \( < 3 \), one case second-line IPI was 3 and in two cases not evaluable due to serum LDH at relapse not being performed. There was no difference in second-line IPI between the two groups \((P = 1.00)\).

### Table 1. Factors associated with relapse after achieving a complete remission at the end of therapy (univariate analysis)

| Variable                      | Relapse \( n = 13 \) | No relapse \( n = 103 \) | \( P \)-value |
|-------------------------------|----------------------|--------------------------|---------------|
| Median age (years)            | 59                   | 59                       | 0.96          |
| PET stage 3/4 at diagnosis    | 11 (84%)             | 35 (34%)                 | 0.005         |
| PET IPI 3–5                   | 8 (62%)              | 29 (28%)                 | 0.02          |
| 2+ EN sites                   | 7 (54%)              | 22 (21%)                 | 0.02          |
| ECOG >1                       | 3 (23%)              | 1 (1%)                   | 0.004         |
| Median LDH (IU l\(^{-1}\))    | 634                  | 514                      | 0.21          |

Abbreviations: EN = extranodal; ECOG = Eastern Cooperative Oncology Group; IPI = international prognostic index; LDH = lactate dehydrogenase. PET IPI is calculated using the stage based on PET rather than contrast CT.

### Table 2. Distribution of PET–CT results as a function of time elapsed from completion of primary chemotherapy for all patients

| Months post treatment | Indeterminate | False positives | True positives (suspected) | True positives (subclinical) | True negatives | Total number of scans |
|-----------------------|---------------|-----------------|---------------------------|-----------------------------|----------------|-----------------------|
| 0–6                   | 1             | 2               | 2                         | 2                           | 91             | 99                    |
| 6–12                  | 3             | 2               | 1                         | 1                           | 96             | 105                   |
| 12–18                 | 2             | 1               | 1                         | 1                           | 68             | 74                    |
| 18–24                 | 1             | 1               | 1                         | 0                           | 66             | 51                    |
| 24–36                 | 0             | 1               | 1                         | 0                           | 31             | 68                    |
| 36–48                 | 0             | 0               | 0                         | 0                           | 22             | 31                    |
| 48 +                  | 0             | 0               | 0                         | 0                           | 0              | 22                    |

Abbreviation: PET–CT = positron emission tomography with computed tomography.

Figure 1. Graphical representation of timing of PET–CT scans performed in the 13 patients who experienced relapse. Follow-up shown until time of relapse; each line represents a single patient. An open circle represents a ‘true negative’ PET–CT scan that is, demonstrating CMR. A closed circle represents a ‘true positive’ that is, scan later proven to represent relapsed lymphoma.
treatment. Two false positives were in patients with baseline IPI $\geq 3$ and four occurred in those with baseline IPI $< 3$. The sites involved were the tonsils ($n = 2$), a cervical lymph node ($n = 1$), mediastinal nodes ($n = 2$) and a peri-duodenal node ($n = 1$). In all cases either biopsy ($n = 3$) or clinical follow-up and resolution ($n = 3$) demonstrated no recurrent lymphoma. There were seven indeterminate scans; two in patients with baseline IPI $\geq 3$ and five in patients with baseline IPI $< 3$. The sites involved were lung in the setting of a chest infection ($n = 1$), tonsils ($n = 2$), cervical ($n = 1$), suboccipital ($n = 1$), mediastinal ($n = 1$) and inguinal nodes ($n = 1$). In all but the final case (biopsy proven recurrent DLBCL), repeat scanning showed resolution of changes. In the terminology used by Zinzani, there were six ‘inconclusive negative’ and one ‘inconclusive positive’ scans (Zinzani et al, 2009). In 67% of false-positive and indeterminate scans combined, the region of interpretative uncertainty was a nodal site involved on baseline PET–CT.

Second malignancies were detected by surveillance PET–CT in eight (7%) patients (Table 3). In addition, PET prompted colonoscopy and polypectomy in one patient. There were two false-positive scans suggesting second malignancy, with PET–CT suggesting possible breast cancer in one patient (mammogram suggesting benign fibroadenoma) and colonic cancer in one patient (colonoscopy normal).

**DISCUSSION**

Our data suggests that PET–CT scanning has both a low yield, and for most patients with DLBCL achieving CMR at the completion of primary therapy is not justified unless there is clinical suspicion of relapse. The only potential subgroup in whom a surveillance strategy warrants further investigation is patients with baseline IPI score $\geq 3$ in the first 18 months from completion of therapy, when the risk of relapse is greatest. In this study, we did not demonstrate a difference in either second-line IPI or OS for patients with subclinical compared with symptomatic relapse, though the number of relapses was small. Underpinning the desire for earlier detection is the theoretical benefit of better outcomes from salvage therapy (Liedtke et al, 2006), although we acknowledge that poor outcomes seen in this group of patients may reflect aggressive biology rather than late detection of relapse. A prospective study of patients with DLBCL and baseline IPI $\geq 3$ in first remission randomised to PET–CT surveillance vs no surveillance with a primary end point of OS would be required to address this issue.

The low rate of relapse among patients achieving CMR at the completion of treatment combined with the lower sensitivity and specificity of CT than PET (Wagner-Johnston and Bartlett, 2011) suggests that diagnostic CT is even less likely to be worthwhile in a surveillance setting. PET–CT detected six (46%) relapses before clinical manifestations, a numerically greater proportion than using CT alone but still a suboptimal surveillance test (Weeks et al, 1991; Guppy et al, 2003). This could be improved by a shorter time-interval surveillance strategy but this may also increase false positives, cost and radiation exposure. Two-thirds of the subclinical relapses would not have been detected using CT alone, further strengthening the case for use of PET–CT over CT alone in surveillance.

We confirm the finding of other investigators that PET–CT is both sensitive and specific for the detection of relapsed DLBCL (Table 4) (Zinzani et al, 2009; Petrausch et al, 2010; El-Galaly et al, 2011). The NPV of 99–100% means that patients with negative scans can be reassured that a CMR truly reflects ongoing remission from DLBCL.

False-positive scans were also infrequent, with six (1.3%) identified. Our findings (86% of inconclusive scans being negative on follow-up) are consistent with the results of Zinzani et al (2009). It is important to recognise common patterns of uptake unlikely to represent lymphomatous recurrence. The majority of false-positive and inconclusive scans occurred in the head and neck or mediastinum, often at sites of lymphomatous involvement at baseline. Increased tonsillar activity is common following chemotherapy, and usually represents reactive lymphoid hyperplasia. Similar findings occur in lymphoid tissue in the mediastinum and para-appendiceal region, with symmetric uptake in the mediastinum and linear uptake in the para-appendiceal region suggesting benign pathology. Mild-to-moderate uptake in cervical nodes, especially following upper respiratory tract infection, should not be mistaken for recurrent lymphoma. It should be highlighted that CT

**Figure 2.** Overall survival by method of detection of relapse, $P = 0.73$.

**Table 3. Second malignancies detected by PET–CT during surveillance scanning**

| Age (years) | Sex | Second tumour     | Months post treatment | Outcome                          |
|------------|-----|-------------------|-----------------------|----------------------------------|
| 80         | M   | Gastric (recurrent)| 7                     | Death (pyloric obstruction)      |
| 65         | F   | Hepatocellular    | 25                    | Resection, alive in remission    |
| 70         | M   | SCC               | 30                    | Palliative radiotherapy, death   |
| 62         | M   | Oesophageal       | 30                    | Resection, survived 28 m         |
| 72         | M   | Prostate          | 6                     | Alive, on anti-androgen Rx       |
| 63         | M   | SCC               | 13                    | T1N1 left piform fossa, curative RT |
| 57         | F   | Breast            | 5                     | Mastectomy, alive in remission   |
| 81         | F   | Breast            | 6                     | Lumpectomy/radiotherapy → remission, death cause unknown 50 months |

Abbreviations: F = female; M = male; PET–CT = positron emission tomography with computed tomography; SCC = squamous cell carcinoma.
alone would have missed two-thirds of subclinical relapses and, therefore, cannot be recommended as an alternative surveillance strategy.

We have not made formal economic evaluation of surveillance PET–CT imaging, however health resources are scarce and in the real world must be considered when recommending any surveillance procedures. The true cost of surveillance includes not only that of the PET–CT scans themselves (an amount which varies considerably between health systems) but the additional costs of investigating indeterminate or false-positive scans (either with repeat interval scanning or unnecessary biopsy). Another potential harm of surveillance PET–CT is additional radiation exposure. The radiation dose varies depending on the CT protocol and sex of the patient, but typically from a combined modality scan exposure. The radiation dose varies depending on the CT protocol and sex of the patient, but typically from a combined modality scan exposure.

Conclusion. Surveillance PET–CT has no role in patients with DLBCL in achieving CMR with the possible exception of patients with baseline IPI \( \geq 3 \) in the 18 months following completion of primary therapy. A prospective study would be required to address this.

**ACKNOWLEDGEMENTS**

CC is funded by a grant from the Victorian Cancer Agency and a New Investigator Scholarship, awarded by the Haematology Society of Australia and New Zealand.

**AUTHOR CONTRIBUTIONS**

CC collected and interpreted the data and wrote the manuscript. JFS designed the study, interpreted the data and wrote the manuscript. MH and RJH interpreted the data and wrote the manuscript. MD, DW, DSR, DAC, KH, HMP, KB and SH provided patients and wrote the manuscript.

**REFERENCES**

A predictive model for aggressive non-Hodgkin’s lymphoma (1993) The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. *N Engl J Med* **329**(4): 987–994.

Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zeleznik AD, Friedberg JW, LaCasce AS (2012) High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. *Leuk Lymphoma* **53**(6): 1113–1116.

Armitage JO (2007) How I treat patients with diffuse large B-cell lymphoma. *Blood* **110**(1): 29–36.

Cheson BD (2011) Role of functional imaging in the management of lymphoma. *J Clin Oncol* **29**(14): 1844–1854.

El-Galaly T, Prakash V, Christiansen I, Madsen J, Johansen P, Boegsted M, Johnsen HE, Bukh A (2011) Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. *Leuk Lymphoma* **52**(4): 597–603.

Elis A, Blickstein D, Klein O, Elav–Ronen R, Manor Y, Lishner M (2002) Detection of relapse in non-Hodgkin’s lymphoma: role of routine follow-up studies. *Am J Hematol* **69**(1): 41–44.

---

**Table 4. Existing literature on the use of PET–CT in post-remission surveillance of diffuse large B-cell lymphoma**

| Author                  | n (% DLBCL) | Surveillance protocol | Median F/U (months) | Type          | Subclinical relapses (%) | False positives (%) | PPV          | NNS          |
|-------------------------|-------------|-----------------------|---------------------|---------------|-------------------------|-------------------|--------------|--------------|
| Zinzani et al (2009)    | 421 (43%)   | 6-monthly for 2 years, then annual for 2 years | 39                  | prospective   | 31%                     | 16/1789 (0.9%)    | NR           | NR           |
| Petrusch et al (2010)   | 75 (100%)   | Non standard          | 16.5                | Retrospective | 13%                     | NR                | 85% NR       |
| Goldschmidt et al (2011)| 125 (65%)   | Non standard          | NR                  | Retrospective | 38%                     | NR                | NR NR NR     |
| El-Galaly et al (2011)  | 52 (83%)    | 6 monthly for 2 years, then annual for 3 year | 18                  | Retrospective | 100%                    | 15/138 (10.3%)    | 21% 34.5     |
| Abel et al (2012)       | 625 (100%)  | Non standard          | 60                  | Retrospective | 26%                     | NR                | NR 120       |
| Current study           | 116 (100%)  | Non standard          | 53                  | Retrospective | 46%                     | 6/456 (1.3%)      | IPI < 3 56%  |
|                         |             |                       |                     |               |                         |                   | IPI > 3 80%  |
|                         |             |                       |                     |               |                         |                   | IPI < 3 92%  |
|                         |             |                       |                     |               |                         |                   | IPI > 3 22%  |

Abbreviations: DLBCL = diffuse large B-cell lymphoma; NNS = number needed to scan to detect one relapse; PPV = positive predictive value; NR = not reported/calculable.

*Only proportion of patients with ‘aggressive Non-Hodgkin Lymphoma’, not specifically DLBCL, reported.*
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Treny M, Bosly A, Ketterer N, Shlip berg O, Hageberg H, Ma D, Briere J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous stem cell transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27): 4184–4190.

Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O (2011) The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 90(2): 165–171.

Guppy AE, Tebbutt NC, Norman A, Cunningham D (2003) The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma 44(1): 123–125.

Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102(6): 1989–1996.

Hicks RJ, Mac Manus MP, Seymour JF (2005) Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 35(3): 165–175.

Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D, Conde E, Tilly H, Cook G, Clark F, Gallamini A, Haynes A, Mounier N, Dreger P, Pfreundschuh M, Sureda A, Party fELW (2008) Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 93(12): 1837–1842.

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spae pen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 25(5): 571–578.

Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O’Connor N, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103(10): 3684–3688.

Leahy MF, Seymour JF, Hicks RJ, Turner JH (2006) Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 24(27): 4418–4425.

Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD (2006) Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 17(6): 909–913.

Meignan M, Gallamini A, Meignan M, Gallamini A, Haouzi C (2009) Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50(8): 1257–1260.

Murano T, Minamimoto R, Senda M, Uno K, Jinnouchi S, Fukuda H, Imura T, Tsukamoto E, Terauchi T, Yoshida T, Oku S, Nishizawa S, Ito K, Oguchi K, Kawamoto M, Nakashima R, Iwata H, Inoue T (2011) Radiation exposure and risk-benefit analysis in cancer using FDG-PET: results of a Japanese nationwide survey. Ann Nuc Med 25(9): 657–666.

National Comprehensive Cancer Centre Network. Non-Hodgkin Lymphoma Clinical Practice Guidelines version 2 (2012).

Petrusch U, Samaras P, Haile SR, Veit-Haibach P, Soyka JD, Knuth A, Hany TF, Mischo A, Renner C, Schafer NG (2010) Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 21(8): 1694–1698.

Rathore N, Eissa HM, Margolin JF, Liu H, Wu MF, Horton T, Kamdar K, Dreyer Z, Steuber P, Rabin KR, Redell M, Allen CE, McClain KL, Guillerman RP, Bollard CM (2012) Pediatric Hodgkin Lymphoma: are we over-scanning our patients? Ped Hematol-Oncol 29(5): 415–423.

Tilly H, Dreyling M. Group ObotEGW (2010) Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5): v172–v174.

Wagner-Johnston ND, Bartlett NL (2011) Role of routine imaging in lymphoma. J Natl Compr Canc Netw 9(5): 575–584 (quiz 585).

Weeks JC, Yeap BY, Canellos GP, Shipp MA (1991) Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 9(7): 1196–1203.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.